Practice and long-term outcome of unprotected left main PCI: real-world data from a nationwide registry.


Journal

Acta cardiologica
ISSN: 1784-973X
Titre abrégé: Acta Cardiol
Pays: England
ID NLM: 0370570

Informations de publication

Date de publication:
Feb 2022
Historique:
pubmed: 9 3 2021
medline: 2 4 2022
entrez: 8 3 2021
Statut: ppublish

Résumé

Percutaneous coronary intervention (PCI) is increasingly performed in significant left main (LM) lesions. Left untreated, the prognosis is poor, but PCI and coronary bypass surgery (CABG) behold risks as well. Additional long-term outcome data might guide future treatment decisions. Between 2012 and 2019, all 6783 patients who underwent LM PCI were prospectively enrolled in a national registry. Patients with prior CABG or prior LM PCI, and patients presenting in cardiogenic shock or after out-of-hospital cardiac arrest were excluded. From the remaining 5284 patients, baseline and procedural data as well as long-term survival were assessed. The annual rate of LM PCI increased from 422 (2.2% of PCIs) in 2012 to 868 in 2018 (3.0%). By 2018, 71% of the interventional cardiologists performed at least 1 LM PCI a year, though only 5 on average. Use of transradial access (TRA) in LM PCI increased from 20.4% in 2012 to 59.5% in 2019. All-cause mortality was 6.0% at 30 days and 18.5% at a mean follow-up of 33.5 months. Independent predictors of higher long-term mortality were older age, diabetes, multivessel disease, an urgent indication, a suboptimal angiographical result, and non-exclusive use of drug-eluting stents. TRAand higher operator and centre LM PCI experience were independent predictors of a lower long-term mortality. LM PCI is associated with high short- and long-term mortality. Use of TRA and higher expertise in LM PCI were associated with better survival.

Sections du résumé

BACKGROUND BACKGROUND
Percutaneous coronary intervention (PCI) is increasingly performed in significant left main (LM) lesions. Left untreated, the prognosis is poor, but PCI and coronary bypass surgery (CABG) behold risks as well. Additional long-term outcome data might guide future treatment decisions.
METHODS METHODS
Between 2012 and 2019, all 6783 patients who underwent LM PCI were prospectively enrolled in a national registry. Patients with prior CABG or prior LM PCI, and patients presenting in cardiogenic shock or after out-of-hospital cardiac arrest were excluded. From the remaining 5284 patients, baseline and procedural data as well as long-term survival were assessed.
RESULTS RESULTS
The annual rate of LM PCI increased from 422 (2.2% of PCIs) in 2012 to 868 in 2018 (3.0%). By 2018, 71% of the interventional cardiologists performed at least 1 LM PCI a year, though only 5 on average. Use of transradial access (TRA) in LM PCI increased from 20.4% in 2012 to 59.5% in 2019. All-cause mortality was 6.0% at 30 days and 18.5% at a mean follow-up of 33.5 months. Independent predictors of higher long-term mortality were older age, diabetes, multivessel disease, an urgent indication, a suboptimal angiographical result, and non-exclusive use of drug-eluting stents. TRAand higher operator and centre LM PCI experience were independent predictors of a lower long-term mortality.
CONCLUSION CONCLUSIONS
LM PCI is associated with high short- and long-term mortality. Use of TRA and higher expertise in LM PCI were associated with better survival.

Identifiants

pubmed: 33683172
doi: 10.1080/00015385.2021.1876402
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

51-58

Auteurs

Peter Kayaert (P)

Department of Cardiology, Universitair Ziekenhuis Gent, Ghent, Belgium.

Mathieu Coeman (M)

Department of Cardiology, Jan Yperman Ziekenhuis, Ypres, Belgium.

Claude Hanet (C)

Department of Cardiology, Clinique Universitaire de l'université catholique de Louvain, Namur, Belgium.

Marc J Claeys (MJ)

Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium.
Department of Cardiovascular Diseases, University of Antwerp, Antwerp, Belgium.

Walter Desmet (W)

Department of Cardiovascular Diseases, University Hospital Leuven, Leuven, Belgium.

Michel De Pauw (M)

Department of Cardiology, Universitair Ziekenhuis Gent, Ghent, Belgium.

Steven Haine (S)

Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium.
Department of Cardiovascular Diseases, University of Antwerp, Antwerp, Belgium.

Yves Taeymans (Y)

Department of Cardiology, Universitair Ziekenhuis Gent, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH